Recently, other drugs, such as fosmanogepix (which inhibits the GPI-anchor biosynthetic enzyme Gwt1), sertraline (a repurposed antidepressant that inhibits serotonin reuptake), tamoxifen (a repurposed breast cancer therapeutic that selectively modulates the estrogen receptor), and VT-1598 (an inhibitor of the ergosterol biosynthetic enzyme Erg11 that disrupts membrane integrity) are at different stages of clinical trial testing and are promising novel antifungal agents to treat cryptococcosis (for a review, see reference 16). This evidence concerns the gene ESR1 and breast carcinoma.